

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

5

## Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Daniel Kolker
Attorney Docket Number	15270J-005912US

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DK	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	
	748	6,610,493	08-26-2003	Citron et al.	
	730	2003/0166557 A1	09-04-2003	Minna et al.	
	702	6,548,640	04-15-2003	Winter	
	725	6,538,124	03-25-2003	Idusogie et al.	
	726	6,528,624	03-04-2003	Idusogie et al.	
	710	6,407,213	06-18-2002	Carter et al.	
	720	6,277,375	08-21-2001	Ward	
	724	6,194,551	02-27-2001	Idusogie et al.	
	704	6,180,370	01-30-2001	Queen et al.	
	747	6,175,057	01-16-2001	Mucke et al.	
	719	6,165,745	12-26-2000	Ward et al.	
	723	6,121,022	09-19-2000	Presta et al.	
	711	6,054,297	04-25-2000	Carter et al.	
	722	5,869,046	02-09-1999	Presta et al.	
	707	5,859,205	01-12-1999	Adair et al.	
	705	5,693,761	12-02-1997	Queen et al.	
	721	5,677,425	10-14-1997	Bodmer et al.	
	717	5,648,260	07-15-1997	Winter et al.	
	718	5,624,821	04-29-1997	Winter et al.	
↓	706	5,585,089	12-17-1996	Queen et al.	
	703	5,225,539	07-06-1993	Winter	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

Examiner  
Signature

/Daniel Kolker/ (09/13/2006)

Date  
Considered

09/13/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60831825

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
DK	738	EP	626 390	A1	11-30-1994			
↓	737	EP	620 276	A1	10-19-1994			
	701	WO	05/014041	A2	02-17-2005			
	757	WO	04/108895	A2, A3	12-16-2004			
	756	WO	03/016467	A2, A3	02-27-2003			
	696	WO	95/06407	A1	03-09-1995			
	736	WO	94/10569	A1	05-11-1994			

Examiner Signature	/Daniel Kolker/ (09/13/2006)	Date Considered	09/13/2006
-----------------------	------------------------------	--------------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/724,575
				Filing Date	November 28, 2000
				First Named Inventor	Schenk
				Art Unit	1649
				Examiner Name	Daniel Kolker
Sheet	3	of	5	Attorney Docket Number	15270J-005912US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
DK	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against $\beta$ A4 Protein: A Potential Probe for Alzheimer's Disease," <u>Bioconjugate Chem.</u> , 5:119-125 (1994).		
	754	BLASBERG et al., "Regional Localization of Glioma-associated Antigen Defined by Monoclonal Antibody 81C6 <i>in Vivo</i> : Kinetics and Implications for Diagnosis and Therapy," <u>Cancer Research</u> , 47:4432-4443 (1987).		
	746	BRAZIL et al., "Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia," <u>J. Biol. Chem.</u> , 275(22):16941-16947 (2000).		
	699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <u>J. Neurosci. Res.</u> , 58:120-129 (1999).		
	745	DEWITT et al., "Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease," <u>Experimental Neurology</u> , 149:329-340 (1998).		
	698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.		
	735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <u>J. Molecular Recognition</u> , 4(2-3):85-91 (1991).		
	741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <u>Int. J. Biochem. &amp; Cell Biol.</u> , 35:1608-1613 (2003).		
	729	KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <u>J. Virology</u> , 61(12):3688-3693 (1987).		
	734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <u>Appl. Pathol.</u> , 3(1-2):39-54 (1985).		
✓	755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <u>J. Molecular Neuroscience</u> , 24:105-113 (2004).		

Examiner Signature	/Daniel Kolker/ (09/13/2006)	Date Considered	09/13/2006
-----------------------	------------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/724,575
				Filing Date	November 28, 2000
				First Named Inventor	Schenk
				Art Unit	1649
				Examiner Name	Daniel Kolker
Sheet	4	of	5	Attorney Docket Number	15270J-005912US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
DK	743	LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?," <u>Immunity &amp; Aging</u> , 1:1-2 (2004).		
	727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J. Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982).		
	742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <u>Critical Rev. Clin. Lab. Sci.</u> , 41(1):1-39 (2004).		
	731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982).		
	744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 ( $\beta$ -amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <u>PNAS</u> , 86:337-341 (1989).		
	732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991).		
	733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996).		
	751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor $\alpha$ ," <u>PNAS</u> , 92:11294-11298 (1995).		
	697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).		
	700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <u>Kidney International</u> , 61:907-912 (2002).		
✓	749	Wikipedia definition of "epitope" printed from internet on 4/26/06.		

Examiner Signature	/Daniel Kolker/ (09/13/2006)	Date Considered	09/13/2006
-----------------------	------------------------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<i>Application Number</i>	09/724,575
				<i>Filing Date</i>	November 28, 2000
				<i>First Named Inventor</i>	Schenk
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Daniel Kolker
Sheet	5	of	5	<i>Attorney Docket Number</i>	15270J-005912US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
DK	752	Wikipedia definition of "antigen" printed from internet on 4/26/06.		
DK	753	Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06.		

Examiner Signature	/Daniel Kolker/ (09/13/2006)	Date Considered	09/13/2006
-----------------------	------------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.